We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+11.56%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$152M
Cap. Flow
+$78.1M
Cap. Flow %
7.15%
Top 10 Hldgs %
44.59%
Holding
100
New
19
Increased
24
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$27.9M
2
DGX icon
Quest Diagnostics
DGX
+$26.1M
3
CAH icon
Cardinal Health
CAH
+$20.8M
4
LLY icon
Eli Lilly
LLY
+$19.4M
5
CRL icon
Charles River Laboratories
CRL
+$15.3M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.6M
3
BPMC
Blueprint Medicines
BPMC
+$12.8M
4
KRYS icon
Krystal Biotech
KRYS
+$10.8M
5
BSX icon
Boston Scientific
BSX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATYR
51
aTyr Pharma
ATYR
$50.5M
$5.32M 0.49%
1,050,000
+350,000
+50% +$1.38M
EXAS
52
DELISTED
Exact Sciences
EXAS
$5.31M 0.49%
+100,000
New +$5.08M
VKTX icon
53
CALL
Viking Therapeutics
VKTX
$3.94B
$5.3M 0.49%
200,000
– –
WAT icon
54
Waters Corp
WAT
$40.7B
$5.24M 0.48%
15,000
-5,000
-25% -$1.72M
GKOS icon
55
Glaukos
GKOS
$10.8B
$5.16M 0.47%
+50,000
New +$4.69M
ELAN icon
56
Elanco Animal Health
ELAN
$11.4B
$5M 0.46%
+350,000
New +$4.09M
COO icon
57
Cooper Companies
COO
$15B
$4.98M 0.46%
+70,000
New +$5.36M
CRSP icon
58
CRISPR Therapeutics
CRSP
$5.18B
$4.86M 0.45%
100,000
-50,000
-33% -$1.93M
TARA icon
59
Protara Therapeutics
TARA
$223M
$4.24M 0.39%
1,400,000
– –
BHVN icon
60
Biohaven
BHVN
$2.12B
$4.23M 0.39%
300,000
+125,000
+71% +$2.23M
SANA icon
61
Sana Biotechnology
SANA
$1B
$4.09M 0.37%
1,500,000
-500,000
-25% -$1.03M
RARE icon
62
Ultragenyx Pharmaceutical
RARE
$2.63B
$3.64M 0.33%
+100,000
New +$3.61M
SRRK icon
63
Scholar Rock
SRRK
$6.34B
$3.54M 0.32%
100,000
-25,000
-20% -$785K
NRIX icon
64
Nurix Therapeutics
NRIX
$2.72B
$3.53M 0.32%
310,000
+35,000
+13% +$378K
JSPR icon
65
Jasper Therapeutics
JSPR
$30.8M
$3.27M 0.3%
590,000
+15,000
+3% +$73.9K
CPRX
66
DELISTED
Catalyst Pharmaceutical
CPRX
$3.25M 0.3%
150,000
– –
ALKS icon
67
Alkermes
ALKS
$8.29B
$2.86M 0.26%
100,000
-50,000
-33% -$1.49M
TERN
68
DELISTED
Terns Pharmaceuticals
TERN
$2.61M 0.24%
700,000
– –
RCUS icon
69
Arcus Biosciences
RCUS
$3.68B
$2.44M 0.22%
+300,000
New +$2.56M
OSCR icon
70
Oscar Health
OSCR
$8.57B
$2.14M 0.2%
100,000
-100,000
-50% -$1.49M
TENX icon
71
Tenax Therapeutics
TENX
$61.7M
$962K 0.09%
167,000
– –
ANRO icon
72
Alto Neuroscience
ANRO
$1.12B
$880K 0.08%
400,000
– –
ACLX
73
CALL
DELISTED
Arcellx
ACLX
– –
-200,000
Closed -$13.1M
ARWR icon
74
Arrowhead Research
ARWR
$12.6B
– –
-175,000
Closed -$2.23M
ASND icon
75
Ascendis Pharma A/S
ASND
$16.7B
– –
-100,000
Closed -$15.6M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Integral Health Asset Management held 100 positions worth $1.09B, up 16% from $940M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $78.1M of net new capital in Q2 2025, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Boston Scientific, an estimated $10.1M trimmed.

  • Integral Health Asset Management's largest Q2 2025 buy was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.
  • Integral Health Asset Management added most to BrightSpring Health Services in Q2 2025, an estimated $9.91M increase.
  • Integral Health Asset Management's biggest Q2 2025 reduction was Boston Scientific, cutting an estimated $10.1M.
  • Integral Health Asset Management fully exited Gilead Sciences in Q2 2025, selling an estimated $19.6M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $1.09B portfolio in Q2 2025.
  • Integral Health Asset Management opened 19 new positions and closed 28 in Q2 2025.
  • Integral Health Asset Management's portfolio value rose 16% quarter-over-quarter to $1.09B.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.